Search Results - "Lord, C. J."

Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer by Herrera-Abreu, M. T., Guan, J., Khalid, U., Ning, J., Costa, M. R., Chan, J., Li, Q., Fortin, J-P., Wong, W. R., Perampalam, P., Biton, A., Sandoval, W., Vijay, J., Hafner, M., Cutts, R., Wilson, G., Frankum, J., Roumeliotis, T. I., Alexander, J., Hickman, O., Brough, R., Haider, S., Choudhary, J., Lord, C. J., Swain, A., Metcalfe, C., Turner, N. C.

“…CDK4/6 inhibition in combination with endocrine therapy is the standard of care for estrogen receptor (ER+) breast cancer, and although cytostasis is…”
Get full text

A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer by Postel-Vinay, S, Bajrami, I, Friboulet, L, Elliott, R, Fontebasso, Y, Dorvault, N, Olaussen, K A, André, F, Soria, J-C, Lord, C J, Ashworth, A

“…Excision repair cross-complementation group 1 (ERCC1) is a DNA repair enzyme that is frequently defective in non-small cell lung cancer (NSCLC). Although low…”
Get full text

Correction: A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D by Rayter, S., Elliott, R., Travers, J., Rowlands, M. G., Richardson, T. B., Boxall, K., Jones, K., Linardopoulos, S., Workman, P., Aherne, W., Lord, C. J., Ashworth, A.

“…An amendment to this paper has been published and can be accessed via a link at the top of the paper…”
Get full text

Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers by Wetterskog, D, Shiu, K-K, Chong, I, Meijer, T, Mackay, A, Lambros, M, Cunningham, D, Reis-Filho, J S, Lord, C J, Ashworth, A

“…The gene encoding the receptor tyrosine kinase ERBB2, also known as HER2, is amplified and/or overexpressed in up to 15% of breast cancers. These tumours are…”
Get full text

Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer by McCabe, N, Cerone, M A, Ohishi, T, Seimiya, H, Lord, C J, Ashworth, A

“…The BRCA1 and BRCA2 proteins are involved in the maintenance of genome stability and germ-line loss-of-function mutations in either BRCA1 or BRCA2 strongly…”
Get full text

Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress by Hewish, M, Martin, S A, Elliott, R, Cunningham, D, Lord, C J, Ashworth, A

“…Background: DNA mismatch repair deficiency is present in a significant proportion of a number of solid tumours and is associated with distinct clinical…”
Get full text

Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours by Rajan, N, Elliott, R, Clewes, O, Mackay, A, Reis-Filho, J S, Burn, J, Langtry, J, Sieber-Blum, M, Lord, C J, Ashworth, A

“…Individuals with germline mutations in the tumour-suppressor gene CYLD are at high risk of developing disfiguring cutaneous appendageal tumours, the defining…”
Get full text

A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D by Rayter, S, Elliott, R, Travers, J, Rowlands, M G, Richardson, T B, Boxall, K, Jones, K, Linardopoulos, S, Workman, P, Aherne, W, Lord, C J, Ashworth, A

“…The PPM1D gene is aberrantly amplified in a range of common cancers and encodes a protein phosphatase that is a potential therapeutic target. However, the…”
Get full text

genomic profile of HER2-amplified breast cancers: the influence of ER status by Marchiò, C, Natrajan, R, Shiu, KK, Lambros, MBK, Rodriguez-Pinilla, SM, Tan, DSP, Lord, CJ, Hungermann, D, Fenwick, K, Tamber, N, Mackay, A, Palacios, J, Sapino, A, Buerger, H, Ashworth, A, Reis-Filho, JS

“…Expression profiling studies have suggested that HER2-amplified breast cancers constitute a heterogeneous group that may be subdivided according to their ER…”
Get full text

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer by Miller, R.E., Leary, A., Scott, C.L., Serra, V., Lord, C.J., Bowtell, D., Chang, D.K., Garsed, D.W., Jonkers, J., Ledermann, J.A., Nik-Zainal, S., Ray-Coquard, I., Shah, S.P., Matias-Guiu, X., Swisher, E.M., Yates, L.R.

“…Homologous recombination repair deficiency (HRD) is a frequent feature of high-grade serous ovarian, fallopian tube and peritoneal carcinoma (HGSC) and is…”
Get full text

RNA interference screening demystified by Lord, C J, Martin, S A, Ashworth, A

“…Genetic screens, where the effects of modifying gene function on cell behaviour are assessed in a systematic fashion, have for some time provided useful…”
Get more information

Efficacy of Beauveria bassiana for control of Tribolium castaneum with reduced oxygen and increased carbon dioxide by Lord, J.C

“…This study investigated the effect of atmosphere modification, a widely adopted means of insect control in stored products, on the efficacy of Beauveria…”
Get full text

The proteasome is involved in determining differential utilization of double-strand break repair pathways by GUDMUNDSDOTTIR, K, LORD, C. J, ASHWORTH, A

“…The DSS1 protein interacts with the breast cancer susceptibility protein BRCA2 that plays an integral role in the repair of DNA double-strand breaks (DSBs)…”
Get full text

A decade of clinical development of PARP inhibitors in perspective by Mateo, J., Lord, C.J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S.B., de Bono, J.S.

“…Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair capacities in tumour cells. DNA damage repair defects are common in…”
Get full text

Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer by Harvey-Jones, E, Raghunandan, M, Robbez-Masson, L, Magraner-Pardo, L, Alaguthurai, T, Yablonovitch, A, Yen, J, Xiao, H, Brough, R, Frankum, J, Song, F, Yeung, J, Savy, T, Gulati, A, Alexander, J, Kemp, H, Starling, C, Konde, A, Marlow, R, Cheang, M, Proszek, P, Hubank, M, Cai, M, Trendell, J, Lu, R, Liccardo, R, Ravindran, N, Llop-Guevara, A, Rodriguez, O, Balmana, J, Lukashchuk, N, Dorschner, M, Drusbosky, L, Roxanis, I, Serra, V, Haider, S, Pettitt, S J, Lord, C J, Tutt, A N J

“…Resistance to therapies that target homologous recombination deficiency (HRD) in breast cancer limits their overall effectiveness. Multiple, preclinically…”
Get more information

Profiles of strontium and barium in Mercenaria mercenaria and Spisula solidissima shells by Stecher, H.A., Krantz, D.E., Lord, C.J., Luther, G.W., Bock, K.W.

“…Cross sections of two Mercenaria mercenaria shells, one modern and one Pleistocene, and one modern Spisula solidissima shell were analyzed for trace metals…”
Get full text

Corrigendum to “Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer”: [Annals of Oncology 33 (2022) 769–785] by Van Baelen, K., Geukens, T., Maetens, M., Tjan-Heijnen, V., Lord, C.J., Linn, S., Bidard, F.-C., Richard, F., Yang, W.W., Steele, R.E., Pettitt, S.J., Van Ongeval, C., De Schepper, M., Isnaldi, E., Nevelsteen, I., Smeets, A., Punie, K., Voorwerk, L., Wildiers, H., Floris, G., Vincent Salomon, A., Derksen, P.W.B., Neven, P., Senkus, E., Sawyer, E., Kok, M., Desmedt, C.

Get full text

Modelling the Cancer Phenotype in the Era of CRISPR-Cas9 Gene Editing by Stewart, J., Banerjee, S., Pettitt, S.J., Lord, C.J.

Get full text

Localization of two insulin-dependent diabetes (Idd) genes to the Idd10 region on mouse Chromosome 3 by Podolin, P L, Denny, P, Armitage, N, Lord, C J, Hill, N J, Levy, E R, Peterson, L B, Todd, J A, Wicker, L S, Lyons, P A

“…Multiple genes control the development of autoimmune diabetes both in humans and in the nonobese diabetic (NOD) strain of mouse. Previously, three…”
Get full text

Genome-wide characterization reveals complex interplay between TP53 and TP63 in response to genotoxic stress by McDade, Simon S, Patel, Daksha, Moran, Michael, Campbell, James, Fenwick, Kerry, Kozarewa, Iwanka, Orr, Nicholas J, Lord, Christopher J, Ashworth, Alan A, McCance, Dennis J

“…In response to genotoxic stress the TP53 tumour suppressor activates target gene expression to induce cell cycle arrest or apoptosis depending on the extent of…”
Get full text